As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.

On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work

outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.

The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.

Tonghua Dongbao Pharmaceutical Co., Ltd.

Tonghua Dongbao Pharmaceutical Co., Ltd.

Company Overview


Tonghua Dongbao is primarily engaged in the research and development, production, and sales of diabetes treatment. The company in recent years started to apply for approval in international markets for its insulin product, which is under various stages of review in the European Union, United States, Sweden, and Poland. In 2016, overseas markets contributed to just over 1% of its total revenue.


Li Yikui


Tonghua, Jilin


(435) 508.8025